Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-418

Lots of teeth gnashing over the past week to be sure, but to me Team IMU have shown great foresight and VISION in their actions.

The intellectual property is excellent in its own right but it is the production facility tie in which most excites me for smooth future progress with the FDA.

Most biomeds treat production as an afterthought in their trial progression. Not Imugene. It seems to me that IMU are showing great confidence in our rapidly approaching trial outcomes (Leslie’s words and body language are a massive tell - she’d be terrible at poker I reckon!).

Remember the best decisions are made not for today but for future, long term benefit.

If we’re sitting on a Royal Flush with ease of production and distribution to follow, I don’t think too many of us are going to be concerned with the SP today or next week….

AIMHO